Re-adapting T cells for cancer therapy: from mouse models to clinical trials

Authors

  • Ingunn M. Stromnes,

    1. Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    2. Department of Immunology, University of Washington, Seattle, WA, USA
    Search for more papers by this author
    • These authors contributed equally to the generation of the data and the preparation of the manuscript.
  • Thomas M. Schmitt,

    1. Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Search for more papers by this author
    • These authors contributed equally to the generation of the data and the preparation of the manuscript.
  • Aude G. Chapuis,

    1. Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Search for more papers by this author
    • These authors contributed equally to the generation of the data and the preparation of the manuscript.
  • Sunil R. Hingorani,

    1. Clinical Research Division and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    2. Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA
    Search for more papers by this author
  • Philip D. Greenberg

    Corresponding author
    1. Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    2. Department of Immunology, University of Washington, Seattle, WA, USA
    3. Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA
    • Correspondence to:

      Philip D. Greenberg

      Program in Immunology

      Clinical Research Division

      Fred Hutchinson Cancer Research Center

      Mail Stop D3-100, P.O. Box 19024

      Seattle, WA 98109-1024, USA

      Tel.: +1 206 667 4462

      Fax: +1 206 667 7983

      e-mail: pgreenberg@fhcrc.org

    Search for more papers by this author

Summary

Adoptive T-cell therapy involves the isolation, expansion, and reinfusion of T lymphocytes with a defined specificity and function as a means to eradicate cancer. Our research has focused on specifying the requirements for tumor eradication with antigen-specific T cells and T cells transduced to express a defined T-cell receptor (TCR) in mouse models and then translating these strategies to clinical trials. Our design of T-cell-based therapy for cancer has reflected efforts to identify the obstacles that limit sustained effector T-cell activity in mice and humans, design approaches to enhance T-cell persistence, develop methods to increase TCR affinity/T-cell functional avidity, and pursue strategies to overcome tolerance and immunosuppression. With the advent of genetic engineering, a highly functional population of T cells can now be rapidly generated and tailored for the targeted malignancy. Preclinical studies in faithful and informative mouse models, in concert with knowledge gained from analyses of successes and limitations in clinical trials, are shaping how we continue to develop, refine, and broaden the applicability of this approach for cancer therapy.

Ancillary